


DECISION ALGORITHM TO ASSIST WITH TESTING, TREATMENT, AND PROPHYLAXIS OF PATIENTS WITH INFLUENZA

Updated December 16, 2010*



References:

1. CDC. Prevention Strategies for Seasonal Influenza In Healthcare Settings: <http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm>
2. CDC. Droplet Precautions Excerpt, HICPAC 2007 Guideline for Isolation Precautions (p.17): <http://www.cdc.gov/hicpac/pdf/isolation/Isolation2007.pdf>
3. CDC. Prevention and Control of Influenza with Vaccines. MMWR 2010; 59(RR-8);1-62. <http://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf>
4. CDC. Guidance for Use of Rapid Influenza Diagnostic Tests for 2010-11 Influenza Season: <http://www.cdc.gov/flu/professionals/diagnosis/>
5. Harper SA, Bradley JS, et al. IDSA Guidelines for Seasonal Influenza in Adults and Children. Clinical Infectious Diseases 2009; 48:1003-32
6. CDC. 2010-11 Influenza Antiviral Medications: Summary for Clinicians. 11/24/10. <http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>
7. American Academy of Pediatrics. Prevention and Control of Influenza in Children 2010-11. Pediatrics. Aug 30, 2010; 126(816-26)
8. Refer to institution-specific guidelines for post-exposure management of Health Care Workers and furlough of HCWs with influenza.

**This algorithm is intended only as a general guide when influenza is circulating in the community, and is based on currently identified strains. Clinical judgment remains an important factor in treatment decisions.*

[From CDC, 2010-2011 Influenza Antiviral Medications: A Summary for Clinicians⁶](#)

Antiviral Medications Recommended for Treatment and Chemoprophylaxis of Influenza, 2010-2011 Influenza Season

Antiviral agent	Activity against	Use	FDA approved for	Not recommended for use in (Contraindications)	Side Effects
Zanamivir (Relenza®)	Influenza A and B	Treatment	7 yrs and older	people with underlying respiratory disease (e.g., asthma, COPD) or heart disease	Allergic reactions: oropharyngeal or facial edema. Side Effects: diarrhea, nausea, sinusitis, nasal signs and symptoms, bronchitis, cough, headache, dizziness, and ear, nose and throat infections.
		Chemo-prophylaxis	5 yrs and older		
Oseltamivir (Tamiflu®)	Influenza A and B	Treatment	1 yr and older	none	Side Effects: nausea, vomiting. Transient neuropsychiatric events (self injury or delirium) mainly reported among Japanese adolescents and adults.
		Chemo-prophylaxis	1 yr and older	none	

Recommended Dosage and Duration of Treatment or Chemoprophylaxis for Influenza Antiviral Medications, 2010-2011 Influenza Season

Antiviral Agent	Use	Children	Adults
Zanamivir (Relenza®)	Treatment	10 mg (2 inhalations) twice daily	10 mg (2 inhalations) twice daily
	Chemo prophylaxis	10 mg (2 inhalations) once daily	10 mg (2 inhalations) once daily
Oseltamivir (Tamiflu®)	Treatment	(Not FDA approved for use in children <1 yr old, but was approved under EUA during the 2009 H1N1 pandemic) If <1 yr old, the dose is 3 mg/kg/dose twice daily	75 mg twice daily
		(Dose varies by child's weight) If ≥1 yr old and weigh 15 kg or less, the dose is 30 mg twice a day.	
		If ≥1 yr old and weigh >15 to 23 kg, the dose is 45 mg twice a day.	
		If ≥1 yr old and weigh >23 to 40 kg, the dose is 60 mg twice a day.	
		If ≥1 yr old and weigh more than 40 kg, the dose is 75 mg twice a day.	
	Chemo prophylaxis	(Not FDA approved for use in children <1 yr old) If child is <3 months old, chemoprophylactic use is not recommended unless situation is judged critical due to limited data on use in this age group.	75 mg once daily
		(Not FDA approved for children <1 yr, but use in children ≥3 months and <1 yr old was approved under EUA during the 2009 H1N1 pandemic) If child ≥3 months and <1 yr old, dose is 3 mg/kg/dose once per day.	
		(Dose varies by child's weight) If ≥1 yr old, and weigh 15 kg or less, the dose is 30 mg once a day.	
		If ≥1 yr old and weigh >15 to 23 kg, the dose is 45 mg once a day.	
		If ≥1 yr old and weigh >23 to 40 kg, the dose is 60 mg once a day.	
If ≥1 yr old and weigh more than 40 kg, the dose is 75 mg once a day.			

Duration of Treatment or Chemoprophylaxis

Treatment	Recommended duration for antiviral treatment is 5 days. Longer treatment courses for patients who remain severely ill after 5 days of treatment can be considered.
Chemo prophylaxis	Recommended duration is 7 days after exposure.
	For control of outbreaks in long-term care facilities and hospital, CDC recommends antiviral chemoprophylaxis for a minimum of 2 weeks, including in vaccinated persons, and up to 1 week after the last known case was identified.